Skip to main content

Articles

Page 4 of 25

  1. Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer’s disease (AD). However, profiles of the biomarkers and the associations with cognition across a spectrum of cogn...

    Authors: Zhenxu Xiao, Xue Wu, Wanqing Wu, Jingwei Yi, Xiaoniu Liang, Saineng Ding, Li Zheng, Jianfeng Luo, Hongchen Gu, Qianhua Zhao, Hong Xu and Ding Ding
    Citation: Alzheimer's Research & Therapy 2021 13:123
  2. Genetic studies have primarily been conducted in European ancestry populations, identifying dozens of loci associated with late-onset Alzheimer’s disease (AD). However, much of AD’s heritability remains unexpl...

    Authors: Andréa R. V. R. Horimoto, Diane Xue, Timothy A. Thornton and Elizabeth E. Blue
    Citation: Alzheimer's Research & Therapy 2021 13:122
  3. Arterial stiffening has emerged as an important risk factor for Alzheimer’s disease (AD) and related dementias. Carotid-femoral pulse wave velocity has been proposed as a non-invasive and reproducible method t...

    Authors: Katherine J. Bangen, Denis S. Smirnov, Lisa Delano-Wood, Christina E. Wierenga, Mark W. Bondi, David P. Salmon and Douglas Galasko
    Citation: Alzheimer's Research & Therapy 2021 13:121
  4. There is an urgent need for objective markers of Alzheimer’s disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response t...

    Authors: Alberto Lleó, Maria Carmona-Iragui, Laura Videla, Susana Fernández, Bessy Benejam, Jordi Pegueroles, Isabel Barroeta, Miren Altuna, Silvia Valldeneu, Mei-Fang Xiao, Desheng Xu, Raúl Núñez-Llaves, Marta Querol-Vilaseca, Sònia Sirisi, Alexandre Bejanin, M. Florencia Iulita…
    Citation: Alzheimer's Research & Therapy 2021 13:119
  5. Impaired self-awareness of memory function, a.k.a. anosognosia, is a common symptom in Alzheimer’s disease (AD); however, its pathological correlates remain unclear. Here, we investigated the impact of amyloid...

    Authors: Geoffroy Gagliardi, Madeline Kuppe, Cristina Lois, Bernard Hanseeuw and Patrizia Vannini
    Citation: Alzheimer's Research & Therapy 2021 13:118
  6. Genome-wide association studies (GWAS) have identified a number of genetic variants for Alzheimer’s disease (AD). However, most GWAS were conducted in individuals of European ancestry, and non-European populat...

    Authors: Hang-Rai Kim, Sang-Hyuk Jung, Jaeho Kim, Hyemin Jang, Sung Hoon Kang, Song Hwangbo, Jun Pyo Kim, So Yeon Kim, Beomsu Kim, Soyeon Kim, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Jae-Won Jang…
    Citation: Alzheimer's Research & Therapy 2021 13:117
  7. Alzheimer disease (AD) is the most common cause of dementia. Preclinical AD is the period during which early AD brain changes are present but cognitive symptoms have not yet manifest. The presence of AD brain ...

    Authors: Sayeh Bayat, Ganesh M. Babulal, Suzanne E. Schindler, Anne M. Fagan, John C. Morris, Alex Mihailidis and Catherine M. Roe
    Citation: Alzheimer's Research & Therapy 2021 13:115
  8. Neuronal hyperactivity related to β-amyloid (Aβ) is considered an early warning sign of Alzheimer disease (AD). Although increasing evidence supports this opinion, the underlying mechanisms are still unknown.

    Authors: Yang Li, Ke Zhu, Ning Li, Xiaotong Wang, Xuansheng Xiao, Linying Li, Lijuan Li, Ying He, Jinglan Zhang, Jiaoyang Wo, Yanqiu Cui, Haixia Huang, Jianliang Zhang, Wei Wang, Xiaomin Wang and Yan Zheng
    Citation: Alzheimer's Research & Therapy 2021 13:114
  9. Although few studies have shown that risk factors for Alzheimer’s disease (AD) are associated with cognitive decline in AD, not much is known whether the impact of risk factors differs between early-onset AD (...

    Authors: Jaeho Kim, Sook-Young Woo, Seonwoo Kim, Hyemin Jang, Junpyo Kim, Jisun Kim, Sung Hoon Kang, Duk L. Na, Juhee Chin, Liana G. Apostolova, Sang Won Seo and Hee Jin Kim
    Citation: Alzheimer's Research & Therapy 2021 13:113
  10. The described relationship between Alzheimer’s disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD p...

    Authors: Maria Vargas-Soria, Maria Jose Carranza-Naval, Angel del Marco and Monica Garcia-Alloza
    Citation: Alzheimer's Research & Therapy 2021 13:112
  11. Challenges have been recognized in healthcare of patients with Alzheimer’s disease (AD) in the COVID-19 pandemic, given a high infection and mortality rate of COVID-19 in these patients. This situation urges t...

    Authors: Nian Xiong, Martin R. Schiller, Jingwen Li, Xiaowu Chen and Zhicheng Lin
    Citation: Alzheimer's Research & Therapy 2021 13:111
  12. Dementia-like cognitive impairment is an increasingly reported complication of SARS-CoV-2 infection. However, the underlying mechanisms responsible for this complication remain unclear. A better understanding ...

    Authors: Yadi Zhou, Jielin Xu, Yuan Hou, James B. Leverenz, Asha Kallianpur, Reena Mehra, Yunlong Liu, Haiyuan Yu, Andrew A. Pieper, Lara Jehi and Feixiong Cheng
    Citation: Alzheimer's Research & Therapy 2021 13:110
  13. Language impairment is an important marker of neurodegenerative disorders. Despite this, there is no universal system of terminology used to describe these impairments and large inter-rater variability can exi...

    Authors: Anthony Yeung, Andrea Iaboni, Elizabeth Rochon, Monica Lavoie, Calvin Santiago, Maria Yancheva, Jekaterina Novikova, Mengdan Xu, Jessica Robin, Liam D. Kaufman and Fariya Mostafa
    Citation: Alzheimer's Research & Therapy 2021 13:109
  14. Subjective cognitive decline, perceived worsening of cognitive ability without apparent performance issues on clinical assessment, may be an important precursor to dementia. While previous cross-sectional rese...

    Authors: Raymond P. Viviano and Jessica S. Damoiseaux
    Citation: Alzheimer's Research & Therapy 2021 13:108
  15. Accelerated long-term forgetting has been identified in preclinical Alzheimer’s disease (AD) and is attributed to a selective impairment of memory consolidation in which the hippocampus plays a key role. As bl...

    Authors: Jianwei Yang, Chaojun Kong, Longfei Jia, Tingting Li, Meina Quan, Yan Li, Diyang Lyu, Fangyu Li, Hongmei Jin, Ying Li, Qigeng Wang and Jianping Jia
    Citation: Alzheimer's Research & Therapy 2021 13:107
  16. In preclinical studies, p38⍺ kinase is implicated in Alzheimer’s disease (AD) pathogenesis. In animal models, it mediates impaired synaptic dysfunction in the hippocampus, causing memory deficits, and is invol...

    Authors: Niels D. Prins, John E. Harrison, Hui-May Chu, Kelly Blackburn, John J. Alam and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2021 13:106
  17. Subjective cognitive decline (SCD) is the subjective perception of a decline in memory and/or other cognitive functions in the absence of objective evidence. Some SCD individuals however may suffer from very e...

    Authors: Federica Ribaldi, Christian Chicherio, Daniele Altomare, Marta Martins, Szymon Tomczyk, Ileana Jelescu, Enrique Maturana, Max Scheffler, Sven Haller, Karl-Olof Lövblad, Michela Pievani, Valentina Garibotto, Matthias Kliegel and Giovanni B. Frisoni
    Citation: Alzheimer's Research & Therapy 2021 13:105
  18. Alzheimer’s disease (AD) is a progressive and irreversible brain disorder. Hippocampus is one of the involved regions and its atrophy is a widely used biomarker for AD diagnosis. We have recently developed Den...

    Authors: Sreevani Katabathula, Qinyong Wang and Rong Xu
    Citation: Alzheimer's Research & Therapy 2021 13:104
  19. Old age, the most important risk factor for Alzheimer’s disease (AD), is associated with thermoregulatory deficits. Brown adipose tissue (BAT) is the main thermogenic driver in mammals and its stimulation, thr...

    Authors: Marine Tournissac, Tra-My Vu, Nika Vrabic, Clara Hozer, Cyntia Tremblay, Koralie Mélançon, Emmanuel Planel, Fabien Pifferi and Frédéric Calon
    Citation: Alzheimer's Research & Therapy 2021 13:103
  20. Neurofilament light in serum (sNfL) is a biomarker for axonal damage with elevated levels in many neurological disorders, including neurodegenerative dementias. Since within-group variation of sNfL is large an...

    Authors: E. A. J. Willemse, P. Scheltens, C. E. Teunissen and E. G. B. Vijverberg
    Citation: Alzheimer's Research & Therapy 2021 13:101
  21. Little is known about the heterogeneous etiology of suspected non-Alzheimer’s pathophysiology (SNAP), a group of subjects with neurodegeneration in the absence of β-amyloid. Using antemortem MRI and pathologic...

    Authors: L. E. M. Wisse, R. de Flores, L. Xie, S. R. Das, C. T. McMillan, J. Q. Trojanowski, M. Grossman, E. B. Lee, D. Irwin, P. A. Yushkevich and D. A. Wolk
    Citation: Alzheimer's Research & Therapy 2021 13:100
  22. Inconsistent positivity thresholds, image analysis pipelines, and quantitative outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) radiotracer in positron emission tomography (P...

    Authors: Sarah K. Royse, Davneet S. Minhas, Brian J. Lopresti, Alice Murphy, Tyler Ward, Robert A. Koeppe, Santiago Bullich, Susan DeSanti, William J. Jagust and Susan M. Landau
    Citation: Alzheimer's Research & Therapy 2021 13:99
  23. The Placebo Group Simulation Approach (PGSA) aims at partially replacing randomized placebo-controlled trials (RPCTs), making use of data from historical control groups in order to decrease the needed number o...

    Authors: Manfred Berres, Andreas U. Monsch and René Spiegel
    Citation: Alzheimer's Research & Therapy 2021 13:97
  24. The relationship between cancer and dementia is triggering growing research interest. Several preclinical studies have provided the biological rationale for the repurposing of specific anticancer agents in Alz...

    Authors: Antonio Ancidoni, Ilaria Bacigalupo, Giulia Remoli, Eleonora Lacorte, Paola Piscopo, Giulia Sarti, Massimo Corbo, Nicola Vanacore and Marco Canevelli
    Citation: Alzheimer's Research & Therapy 2021 13:96
  25. Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker stat...

    Authors: Maitee Rosende-Roca, Carla Abdelnour, Ester Esteban, Juan Pablo Tartari, Emilio Alarcon, Juliana Martínez-Atienza, Antonio González-Pérez, María E. Sáez, Asunción Lafuente, Mar Buendía, Ana Pancho, Nuria Aguilera, Marta Ibarria, Susana Diego, Sara Jofresa, Isabel Hernández…
    Citation: Alzheimer's Research & Therapy 2021 13:95
  26. Alzheimer’s disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as ...

    Authors: Freyja Aichholzer, Hans-Wolfgang Klafki, Isabella Ogorek, Jonathan Vogelgsang, Jens Wiltfang, Norbert Scherbaum, Sascha Weggen and Oliver Wirths
    Citation: Alzheimer's Research & Therapy 2021 13:94
  27. We aimed to investigate the tau biomarker discrepancies of Alzheimer’s disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal fluid (CSF) p-tau181, and AV1451 positron emission...

    Authors: Yu Guo, Yu-Yuan Huang, Xue-Ning Shen, Shi-Dong Chen, Hao Hu, Zuo-Teng Wang, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:93
  28. Identifying novel therapeutic targets is crucial for the successful development of drugs. However, the cost to experimentally identify therapeutic targets is huge and only approximately 400 genes are targets f...

    Authors: Shingo Tsuji, Takeshi Hase, Ayako Yachie-Kinoshita, Taiko Nishino, Samik Ghosh, Masataka Kikuchi, Kazuro Shimokawa, Hiroyuki Aburatani, Hiroaki Kitano and Hiroshi Tanaka
    Citation: Alzheimer's Research & Therapy 2021 13:92
  29. In view of reported associations between high adiposity, particularly in midlife and late-life dementia risk, we aimed to determine associations between body mass index (BMI), and BMI changes across adulthood ...

    Authors: Christopher A. Lane, Josephine Barnes, Jennifer M. Nicholas, John W. Baker, Carole H. Sudre, David M. Cash, Thomas D. Parker, Ian B. Malone, Kirsty Lu, Sarah-Naomi James, Ashvini Keshavan, Sarah Buchanan, Sarah Keuss, Heidi Murray-Smith, Andrew Wong, Elizabeth Gordon…
    Citation: Alzheimer's Research & Therapy 2021 13:91
  30. Very-early-onset Alzheimer’s disease (young-AD) differentiates from late-onset AD (old-AD) by a predominant involvement of the parietal neocortex leading to atypical presentations. The diagnosis of AD is often...

    Authors: Pauline Olivieri, Lorraine Hamelin, Julien Lagarde, Valérie Hahn, Elodie Guichart-Gomez, Carole Roué-Jagot and Marie Sarazin
    Citation: Alzheimer's Research & Therapy 2021 13:90
  31. Functional decline in Alzheimer’s disease (AD) is typically measured using single-time point subjective rating scales, which rely on direct observation or (caregiver) recall. Remote monitoring technologies (RM...

    Authors: Marijn Muurling, Casper de Boer, Rouba Kozak, Dorota Religa, Ivan Koychev, Herman Verheij, Vera J. M. Nies, Alexander Duyndam, Meemansa Sood, Holger Fröhlich, Kristin Hannesdottir, Gul Erdemli, Federica Lucivero, Claire Lancaster, Chris Hinds, Thanos G. Stravopoulos…
    Citation: Alzheimer's Research & Therapy 2021 13:89
  32. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jing Di, Ibrar Siddique, Zizheng Li, Ghattas Malki, Simon Hornung, Suman Dutta, Ian Hurst, Ella Ishaaya, Austin Wang, Sally Tu, Ani Boghos, Ida Ericsson, Frank-Gerrit Klärner, Thomas Schrader and Gal Bitan
    Citation: Alzheimer's Research & Therapy 2021 13:88

    The original article was published in Alzheimer's Research & Therapy 2021 13:6

  33. The cholinergic system and M1 receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M1 receptor partial agonist HTL0018318 is under development for the symptomatic ...

    Authors: Charlotte Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Robert Jan Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, David M. Cross, Geert Jan Groeneveld and Pradeep J. Nathan
    Citation: Alzheimer's Research & Therapy 2021 13:87
  34. Blood neurofilament light (Nfl) and total-tau (t-tau) have been described to be increased in several neurological conditions, including prion diseases and other neurodegenerative dementias. Here, we aim to det...

    Authors: Inga Zerr, Anna Villar-Piqué, Peter Hermann, Matthias Schmitz, Daniela Varges, Isidre Ferrer, Joachim Riggert, Henrik Zetterberg, Kaj Blennow and Franc Llorens
    Citation: Alzheimer's Research & Therapy 2021 13:86
  35. The Clock Drawing Test (CDT) and Rey–Osterrieth Complex Figure Test (RCFT) are widely used as a part of neuropsychological test batteries to assess cognitive function. Our objective was to confirm the predicti...

    Authors: Young Chul Youn, Jung-Min Pyun, Nayoung Ryu, Min Jae Baek, Jae-Won Jang, Young Ho Park, Suk-Won Ahn, Hae-Won Shin, Kwang-Yeol Park and Sang Yun Kim
    Citation: Alzheimer's Research & Therapy 2021 13:85
  36. The primary study objective of this retrospective academic memory clinic-based observational longitudinal study was to investigate the prognostic value of a cerebrospinal fluid (CSF)-based ATN classification f...

    Authors: Koen Delmotte, Jolien Schaeverbeke, Koen Poesen and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2021 13:84
  37. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Woo Shik Shin, Jing Di, Qin Cao, Binsen Li, Paul M. Seidler, Kevin A. Murray, Gal Bitan and Lin Jiang
    Citation: Alzheimer's Research & Therapy 2021 13:83

    The original article was published in Alzheimer's Research & Therapy 2019 11:86

  38. Detecting subtle-to-moderate biomarker changes such as those in amyloid PET imaging becomes increasingly relevant in the context of primary and secondary prevention of Alzheimer’s disease (AD). This work aimed...

    Authors: Isadora Lopes Alves, Fiona Heeman, Lyduine E. Collij, Gemma Salvadó, Nelleke Tolboom, Natàlia Vilor-Tejedor, Pawel Markiewicz, Maqsood Yaqub, David Cash, Elizabeth C. Mormino, Philip S. Insel, Ronald Boellaard, Bart N. M. van Berckel, Adriaan A. Lammertsma, Frederik Barkhof and Juan Domingo Gispert
    Citation: Alzheimer's Research & Therapy 2021 13:82
  39. We aimed to investigate the associations between healthy lifestyles and Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF).

    Authors: Xiao-He Hou, Wei Xu, Yan-Lin Bi, Xue-Ning Shen, Ya-Hui Ma, Qiang Dong, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:81
  40. Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomize...

    Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings
    Citation: Alzheimer's Research & Therapy 2021 13:80

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:70

  41. CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profil...

    Authors: James D. Doecke, Cindy Francois, Christopher J. Fowler, Erik Stoops, Pierrick Bourgeat, Stephanie R. Rainey-Smith, Qiao-Xin Li, Colin L. Masters, Ralph N. Martins, Victor L. Villemagne, Steven J. Collins and Hugo Marcel Vanderstichele
    Citation: Alzheimer's Research & Therapy 2021 13:79
  42. Pain is common among individuals with Alzheimer’s disease and related dementias (ADRD), and use of opioids has been increasing over the last decade. Yet, it is unclear to what extent opioids are appropriately ...

    Authors: Yu-Jung Jenny Wei, Siegfried Schmidt, Cheng Chen, Roger B. Fillingim, M. Carrington Reid, Steven DeKosky, Laurence Solberg, Marco Pahor, Babette Brumback and Almut G. Winterstein
    Citation: Alzheimer's Research & Therapy 2021 13:78
  43. There is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19).

    Authors: Agathe Vrillon, Elsa Mhanna, Clément Aveneau, Manon Lebozec, Lina Grosset, Diane Nankam, Fernanda Albuquerque, Raphaelle Razou Feroldi, Barbara Maakaroun, Iana Pissareva, Dalenda Cherni Gherissi, Julien Azuar, Véronique François, Claire Hourrègue, Julien Dumurgier, Lisette Volpe-Gillot…
    Citation: Alzheimer's Research & Therapy 2021 13:77
  44. Aducanumab is an anti-amyloid-β (Aβ) antibody that achieved reduced amyloid pathology in Alzheimer’s disease (AD) trials; however, it is controversial whether it also improved cognition, which has been suggest...

    Authors: Gerhard Leinenga, Wee Kiat Koh and Jürgen Götz
    Citation: Alzheimer's Research & Therapy 2021 13:76
  45. We examined in cognitively intact older adults the relative weight of cognitive, genetic, structural and amyloid brain imaging variables for predicting cognitive change over a 4-year time course.

    Authors: Jolien M. Schaeverbeke, Silvy Gabel, Karen Meersmans, Emma S. Luckett, Steffi De Meyer, Katarzyna Adamczuk, Natalie Nelissen, Valerie Goovaerts, Ahmed Radwan, Stefan Sunaert, Patrick Dupont, Koen Van Laere and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2021 13:75
  46. Subjective cognitive decline (SCD) represents a cognitively normal state but at an increased risk for developing Alzheimer’s disease (AD). Recognizing the glucose metabolic biomarkers of SCD could facilitate t...

    Authors: Qiu-Yue Dong, Tao-Ran Li, Xue-Yan Jiang, Xiao-Ni Wang, Ying Han and Jie-Hui Jiang
    Citation: Alzheimer's Research & Therapy 2021 13:74